Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RESEARCH TOOLSreports
Holding RNAC?
Track your performance easily
RNAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.67 - $42.60
Previous Close$17.33
Volume423.33K
Average Volume (3M)103.77K
Market Cap
$440.44M
Enterprise Value$235.89M
Total Cash (Recent Filing)$219.20M
Total Debt (Recent Filing)$14.65M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Mar 06, 2025EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-52.64
Shares Outstanding25,414,898
10 Day Avg. Volume142,905
30 Day Avg. Volume103,774
Standard Deviation0.25
R-Squared0.02
Alpha0.00931
Financial Highlights & Ratios
Price to Book (P/B)577.67
Price to Sales (P/S)9.05
Price to Cash Flow (P/CF)7.90
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.93
Enterprise Value/Gross Profit9.07
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$40.25Price Target Upside132.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Cartesian Therapeutics News
PremiumCompany Announcements
Cartesian Therapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressRNAC plans to initiate a Phase 3 study of lead program Descartes-08 in generalized myasthenia gravis, indicating progress in their clinical trials.
Financial StabilityCartesian ended 3Q24 with cash of ~$221M to support operations into mid-2027, including the completion of the Phase 3 MG trial.
Therapeutic AdvantageCartesian's cell therapy approach is positioned favorably among peers, with its mRNA modality offering advantages in autoimmunity treatments.
Bears Say
Clinical RisksRisks include, but are not limited to: (1) delays in advancing pipeline candidates through clinical assessment; (2) failure to generate favorable clinical data from ongoing programs, particularly Descartes-08 in MG; and (3) possible long-term dilution risk.
EarningsCartesian reported a net loss of $1.13 per share, which was higher than the estimated net loss of $0.90 per share.
Price TargetThe price target for Cartesian has been adjusted down to $41 per share, indicating a reduction from the previous target.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $11.66 and its highest was $42.60 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Currently, no data Available
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$0.802 by -$0.328.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 25,414,898 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.13 in its last earnings report, missing expectations of -$0.802. Following the earnings report the stock price went down -0.384%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Among the largest hedge funds holding Cartesian Therapeutics’s share is Delphi Financial Group, Inc.. It holds Cartesian Therapeutics’s shares valued at 595K.
---
Cartesian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.25 (132.26% Upside)
$40.25 (132.26% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Decreased
By 442.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-40.42%
12-Months-Change
Fundamentals
Return on Equity
-938.38%
Trailing 12-Months
Asset Growth
329.41%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
---
RNAC Earnings Call
Q2 2023
0:00 / 0:00
---
RNAC Stock 12 Month Forecast
Average Price Target
$40.25
▲(132.26% Upside)
Technical Analysis
Best Analysts Covering RNAC
1 Year
---